Suppr超能文献

BAP1 核去泛素化酶通过与 DNA-PK 的相互作用参与双链 DNA 修复的非同源末端连接途径。

The BAP1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK.

机构信息

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Department of Hygiene, Kawasaki Medical University, Okayama, Japan.

出版信息

Oncogene. 2024 Apr;43(15):1087-1097. doi: 10.1038/s41388-024-02966-w. Epub 2024 Feb 21.

Abstract

BRCA1-associated protein 1 (BAP1) has emerged as a major tumor suppressor gene in diverse cancer types, notably in malignant pleural mesothelioma (DPM), and has also been identified as a germline cancer predisposition gene for DPM and other select cancers. However, its role in the response to DNA damage has remained unclear. Here, we show that BAP1 inactivation is associated with increased DNA damage both in Met-5A human mesothelial cells and human DPM cell lines. Through proteomic analyses, we identified PRKDC as an interaction partner of BAP1 protein complexes in DPM cells and 293 T human embryonic kidney cells. PRKDC encodes the catalytic subunit of DNA protein kinase (DNA-PKcs) which functions in the nonhomologous end-joining (NHEJ) pathway of DNA repair. Double-stranded DNA damage resulted in prominent nuclear expression of BAP1 in DPM cells and phosphorylation of BAP1 at serine 395. A plasmid-based NHEJ assay confirmed a significant effect of BAP1 knockdown on cellular NHEJ activity. Combination treatment with X-ray irradiation and gemcitabine (as a radiosensitizer) strongly suppressed the growth of BAP1-deficient cells. Our results suggest reciprocal positive interactions between BAP1 and DNA-PKcs, based on phosphorylation of BAP1 by the latter and deubiquitination of DNA-PKcs by BAP1. Thus, functional interaction of BAP1 with DNA-PKcs supports a role for BAP1 in NHEJ DNA repair and may provide the basis for new therapeutic strategies and new insights into its role as a tumor suppressor.

摘要

BRCA1 相关蛋白 1(BAP1)已成为多种癌症类型中的主要肿瘤抑制基因,尤其是恶性胸膜间皮瘤(DPM),并且已被确定为 DPM 和其他精选癌症的种系癌症易感性基因。然而,其在 DNA 损伤反应中的作用仍不清楚。在这里,我们表明 BAP1 失活与 Met-5A 人胸膜间皮细胞和人 DPM 细胞系中增加的 DNA 损伤有关。通过蛋白质组学分析,我们鉴定出 PRKDC 是 DPM 细胞和 293T 人胚肾细胞中 BAP1 蛋白复合物的相互作用伙伴。PRKDC 编码 DNA 蛋白激酶(DNA-PKcs)的催化亚基,该酶在 DNA 修复的非同源末端连接(NHEJ)途径中起作用。双链 DNA 损伤导致 DPM 细胞中 BAP1 的核内表达明显增加,并使 BAP1 的丝氨酸 395 发生磷酸化。基于 NHEJ 的质粒测定证实 BAP1 敲低对细胞 NHEJ 活性有显著影响。X 射线照射和吉西他滨(作为放射增敏剂)联合治疗强烈抑制了 BAP1 缺陷细胞的生长。我们的结果表明 BAP1 和 DNA-PKcs 之间存在相互的正相互作用,这是基于后者对 BAP1 的磷酸化和 BAP1 对 DNA-PKcs 的去泛素化。因此,BAP1 与 DNA-PKcs 的功能相互作用支持 BAP1 在 NHEJ DNA 修复中的作用,并为新的治疗策略提供了依据,并深入了解其作为肿瘤抑制因子的作用。

相似文献

2
Genetic interaction between DNA repair factors PAXX, XLF, XRCC4 and DNA-PKcs in human cells.
FEBS Open Bio. 2019 Jul;9(7):1315-1326. doi: 10.1002/2211-5463.12681. Epub 2019 Jun 12.
4
An Intrinsically Disordered APLF Links Ku, DNA-PKcs, and XRCC4-DNA Ligase IV in an Extended Flexible Non-homologous End Joining Complex.
J Biol Chem. 2016 Dec 30;291(53):26987-27006. doi: 10.1074/jbc.M116.751867. Epub 2016 Nov 14.
5
Germline mutations in BAP1 impair its function in DNA double-strand break repair.
Cancer Res. 2014 Aug 15;74(16):4282-94. doi: 10.1158/0008-5472.CAN-13-3109. Epub 2014 Jun 3.
7
Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):285-90. doi: 10.1073/pnas.1309085110. Epub 2013 Dec 17.
8
BAP1 promotes the repair of UV-induced DNA damage via PARP1-mediated recruitment to damage sites and control of activity and stability.
Cell Death Differ. 2022 Dec;29(12):2381-2398. doi: 10.1038/s41418-022-01024-w. Epub 2022 May 30.

引用本文的文献

1
An overview of BAP1 biological functions and current therapeutics.
Biochim Biophys Acta Rev Cancer. 2025 Apr;1880(2):189267. doi: 10.1016/j.bbcan.2025.189267. Epub 2025 Jan 21.
2
Key molecular DNA damage responses of human cells to radiation.
Front Cell Dev Biol. 2024 Jul 10;12:1422520. doi: 10.3389/fcell.2024.1422520. eCollection 2024.

本文引用的文献

2
Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis, and Treatment.
Annu Rev Pathol. 2024 Jan 24;19:11-42. doi: 10.1146/annurev-pathol-042420-092719. Epub 2023 Sep 18.
3
BAP1 as a guardian of genome stability: implications in human cancer.
Exp Mol Med. 2023 Apr;55(4):745-754. doi: 10.1038/s12276-023-00979-1. Epub 2023 Apr 3.
4
BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms.
Oncogene. 2023 Feb;42(8):572-585. doi: 10.1038/s41388-022-02577-3. Epub 2022 Dec 22.
5
7
Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in Gene.
JTO Clin Res Rep. 2021 Sep 17;2(10):100231. doi: 10.1016/j.jtocrr.2021.100231. eCollection 2021 Oct.
8
Proteomic analysis identifies novel binding partners of BAP1.
PLoS One. 2021 Sep 30;16(9):e0257688. doi: 10.1371/journal.pone.0257688. eCollection 2021.
9
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.
Lancet Respir Med. 2021 Jun;9(6):593-600. doi: 10.1016/S2213-2600(20)30390-8. Epub 2021 Jan 27.
10
Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma.
Mol Cancer Res. 2021 Feb;19(2):215-222. doi: 10.1158/1541-7786.MCR-20-0434. Epub 2020 Oct 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验